GLYC News and Press, GlycoMimetics Inc. From 06/02/22

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that the Company will participate at the Jefferies 2022 Healthcare Conference, on June 8 th , in New York, NY. Chief Executive Officer Harout Semerjian and Chief Financial Officer Brian Hahn will attend in person. Research Analy...

GlycoMimetics, Inc. (GLYC) Q1 2022 Results Conference Call April 28, 2022 08:30 AM ET Company Participants Shari Annes - IR Harout Semerjian - CEO Brian Hahn - CFO Armand Girard - Chief Business Officer Conference Call Participants Ed White - H.C. Wainwright Boris Peaker - Cowen Roger Song - ...

Image source: The Motley Fool. GlycoMimetics (NASDAQ: GLYC) Q1 2022 Earnings Call Apr 28, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: GlycoMimetics (GLYC) Q1 2022 Earnings Call Transcript

GlycoMimetics press release (NASDAQ:GLYC): Q1 GAAP EPS of -$0.28 beats by $0.03. Cash and cash equivalents of $76.5M. There was no revenue recognized during the quarter. “During the first quarter, we advanced our transformation from a research company to a commercially-focused organiza...

Mid-year 2023 projected for events trigger of the GlycoMimetics-sponsored pivotal Phase 3 trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML). Investigational new drug (IND)-enabling 28-day toxicity studies and GMP manufacturing com...

GlycoMimetics (NASDAQ:GLYC) is scheduled to announce Q1 earnings results on Wednesday, April 27th, after market close. The consensus EPS Estimate is -$0.32 (-14.3% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward....

GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report first quarter financial results on Thursday, April 28, 2022, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216)...

GlycoMimetics Inc. (NASDAQ:GLYC) traded today at a new 52-week high of $26.00. Approximately 69.1 million shares have changed hands today, as compared to an average 30-day volume of 181,000 shares. In the past 52 weeks, GlycoMimetics Inc. share prices are bracketed by a current low of $1...

Investigator-sponsored trials keep piling up. Strength of indications beyond overall survival. Recent hiring spree of executives with commercial experience. Valuation, opportunity, and risk. For further details see: GlycoMimetics' Uproleselan: Secondary Reasons To Ow...

Data delay for AML therapy is most likely due to a positive OS trend. Uproleselan AML trial is fully enrolled with data due in 2023. GlycoMimetics is woefully undervalued, but not without risk. For further details see: GlycoMimetics Positive Data For AML Therapy Increasi...